1-2 of 2
Pam McKay
Close
Sort by
Journal Articles

Impact of MYC and BCL2 double expression on outcomes in primary CNS lymphoma: a UK multicenter analysis

Edward Poynton, Emily Chernucha, James Day, Catherine Prodger, David Hopkins, Pallav Rakesh, Tess O’Neill, Nisha Thakrar, Ayse Akarca, Esraa Jamal, Ayesha Ali, Amy A. Kirkwood, Sabine Pomplun, Teresa Marafioti, Maria Calaminici, Paul Greaves, Sridhar Chaganti, Pam McKay, Jeffery Smith, Toby A. Eyre, Nicolas Martinez-Calle, Kate Cwynarski, Christopher P. Fox, Jessica Okosun
Journal: Blood Advances
Blood Adv (2024) 8 (7): 1772–1775.
https://doi.org/10.1182/bloodadvances.2023011426
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Clinical Trials & Observations
Loretta J. Nastoupil, Georg Hess, Miguel A. Pavlovsky, Iwona Danielewicz, Jane Freeman, Alejandro Martin García-Sancho, Valeria Glazunova, Andrew Grigg, Jing-Zhou Hou, Ann Janssens, Seok Jin Kim, Zvenyslava Masliak, Pam McKay, Francesco Merli, Wataru Munakata, Hirokazu Nagai, Muhit Özcan, Meir Preis, Tingyu Wang, Melissa Rowe, Monelle Tamegnon, Rui Qin, Todd Henninger, Madeliene Curtis, Donne Bennett Caces, Catherine Thieblemont, Gilles Salles
Journal: Blood Advances
Blood Adv (2023) 7 (22): 7141–7150.
https://doi.org/10.1182/bloodadvances.2023010298
Published: 2023
Includes: Supplemental data